Tomasz M. Szczepanski
Expertise in
9
conditions

Tomasz M. Szczepanski

Zabrze, SL, PL 
Expertise in
9
conditions
Zabrze, SL, PL 

Overview

Tomasz Szczepanski practices practicing medicine in Zabrze, Poland.

Mr. Szczepanski is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Adult T-Cell Leukemia, Nijmegen Breakage Syndrome, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 149 peer reviewed articles and participating in 1 clinical trial.

Gender

Male

Locations

Zabrze, SL, Poland
Other Locations
Katowice, SL 40055, Poland
Lublin, LU, Poland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
Enrollment Status: Terminated
Publish Date: October 02, 2025
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 1/Phase 2

149 Total Publications

KSR2 is a novel oncogene in TAL1 subtype of T-cell acute lymphoblastic leukemia with potential clinical and prognostic implications.
KSR2 is a novel oncogene in TAL1 subtype of T-cell acute lymphoblastic leukemia with potential clinical and prognostic implications.
Journal: Haematologica
Published: June 30, 2026

Frequently Asked Questions about Tomasz M. Szczepanski

Is Tomasz M. Szczepanski a top-rated expert for Acute Lymphoblastic Leukemia (ALL)?

MediFind is an objective health platform that identifies experts based on real-world data. Tomasz M. Szczepanski is classified as an Elite expert for Acute Lymphoblastic Leukemia (ALL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Tomasz M. Szczepanski participate in research or clinical trials?

Yes. Tomasz M. Szczepanski has published 149 articles and abstracts on conditions like Acute Lymphoblastic Leukemia (ALL). You can view a list of Tomasz M. Szczepanski's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Szczepanski's expertise for a condition
ConditionClose
View All 37 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile